[CALA] Calithera Biosciences, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 3.5 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart CALA

Refresh chart

Strongest Trends Summary For CALA

CALA is in the medium-term down -41% below S&P in 2 months and down -63% below S&P in 8 months. In the long-term down -85% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Its lead product candidate includes CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. The company was founded in 2010 and is headquartered in South San Francisco, California.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-1.66 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-8.67
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-20.57% ROE-21.41% ROI
Current Ratio25.65 Quick Ratio Long Term Debt/Equity Debt Ratio0.04
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities10 K Cash From Investing Activities-20.47 M Cash From Operating Activities-7.63 M Gross Profit
Net Profit-7.86 M Operating Profit-7.87 M Total Assets96.87 M Total Current Assets90.31 M
Total Current Liabilities3.52 M Total Debt Total Liabilities3.77 M Total Revenue
Technical Data
High 52 week6.75 Low 52 week2.52 Last close2.6 Last change1.96%
RSI26.01 Average true range0.26 Beta1.45 Volume180.6 K
Simple moving average 20 days-15.61% Simple moving average 50 days-28.08% Simple moving average 200 days-46.18%
Performance Data
Performance Week-4.41% Performance Month-36.59% Performance Quart-39.53% Performance Half-59.25%
Performance Year-59.06% Performance Year-to-date-42.22% Volatility daily4.51% Volatility weekly10.1%
Volatility monthly20.69% Volatility yearly71.67% Relative Volume2060.39% Average Volume340.44 K
New High New Low

News

2019-11-12 16:06:00 | Calithera Biosciences Reports Third Quarter 2019 Financial Results and Recent Highlights

2019-11-05 08:01:00 | Calithera to Present Preclinical Data from IL4I1 and CD73 Programs at the Society for Immunotherapy of Cancer SITC Annual Meeting

2019-11-04 08:00:00 | Calithera Biosciences to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019

2019-10-19 09:23:18 | Read This Before Selling Calithera Biosciences, Inc. NASDAQ:CALA Shares

2019-10-18 10:23:24 | These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year

2019-10-07 09:54:01 | Calithera CALA Completes Enrollment in Mid-Stage RCC Study

2019-10-03 07:05:00 | Calithera Biosciences Completes Patient Enrollment in Randomized CANTATA Trial of Telaglenastat and Cabozantinib in Advanced Renal Cell Carcinoma

2019-10-01 16:05:00 | Calithera Announces Acceptance of Two Abstracts for Presentation at the 2019 Society for Immunotherapy of Cancer SITC Annual Meeting

2019-09-29 10:30:00 | New Data Presented at ESMO Congress 2019 from the Arginase Inhibitor INCB001158 Alone and in Combination with Pembrolizumab

2019-09-28 02:30:00 | Data From Randomized Phase 2 ENTRATA Study Demonstrate Telaglenastat with Everolimus Improves Progression-Free Survival in Renal Cell Carcinoma

2019-09-27 09:28:01 | Calithera Biosciences Enters Oversold Territory

2019-09-26 18:05:00 | Calithera to Host Webcast Conference Call for Analysts and Investors During European Society for Medical Oncology ESMO Congress 2019

2019-09-26 12:00:04 | Implied Volatility Surging for Calithera CALA Stock Options

2019-09-25 08:05:00 | Calithera to Present at the 2019 Cantor Global Healthcare Conference

2019-09-19 10:06:40 | Calithera Biosciences, Inc. NASDAQ:CALA: Is It Growing Too Fast?

2019-08-28 08:00:00 | Calithera to Participate in Wells Fargo Healthcare Conference and Citi 14th Annual Biotech Conference

2019-08-23 09:11:52 | Is Calithera Biosciences, Inc.'s NASDAQ:CALA CEO Pay Justified?

2019-08-10 09:57:34 | Edited Transcript of CALA earnings conference call or presentation 8-Aug-19 9:00pm GMT

2019-08-08 16:05:00 | Calithera Biosciences Reports Second Quarter 2019 Financial Results and Recent Highlights

2019-08-01 07:07:00 | Calithera Biosciences to Report Second Quarter 2019 Financial Results on Thursday, August 8, 2019

2019-07-24 10:40:51 | Does Calithera Biosciences, Inc. NASDAQ:CALA Have A High Beta?

2019-07-02 08:00:00 | Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with Pfizer’s CDK4/6 Inhibitor Palbociclib

2019-06-27 19:15:02 | Calithera Biosciences Inc CALA PRESIDENT AND CEO Susan Molineaux Bought $200,208 of Shares

2019-06-21 16:04:00 | Calithera Biosciences, Inc. Announces Closing of Public Offering and Exercise in Full of Option to Purchase Additional Shares

2019-06-18 23:00:00 | Calithera Biosciences, Inc. Prices Public Offering of 12,500,000 shares of Common Stock

2019-06-18 13:16:37 | Did You Miss Calithera Biosciences's NASDAQ:CALA 37% Share Price Gain?

2019-06-17 16:01:00 | Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock

2019-06-17 10:08:24 | Health Care Digest: Not-so-secret target of new UC-GSK alliance, East Bay toolmaker's big round and more

2019-06-17 10:04:42 | Calithera's Kidney Cancer Drug Doubles Progression-Free Survival Vs. Chemotherapy

2019-06-17 06:00:00 | Calithera Achieves Positive Topline Results in Randomized Phase 2 ENTRATA Study of Telaglenastat with Everolimus in Renal Cell Carcinoma

2019-05-14 12:34:47 | Calithera Biosciences, Inc. CALA Q1 2019 Earnings Call Transcript

2019-05-10 18:08:28 | Edited Transcript of CALA earnings conference call or presentation 9-May-19 9:00pm GMT

2019-05-10 05:14:17 | Calithera: 1Q Earnings Snapshot

2019-05-09 16:06:00 | Calithera Biosciences Reports First Quarter 2019 Financial Results and Recent Highlights 

2019-05-02 10:32:02 | Analysts Estimate Calithera CALA to Report a Decline in Earnings: What to Look Out for

2019-04-25 07:34:54 | How Many Calithera Biosciences, Inc. NASDAQ:CALA Shares Do Institutions Own?

2019-04-02 07:05:00 | Calithera Biosciences Presents New Preclinical Data for CB-708 at AACR Annual Meeting 2019

2019-03-27 17:39:09 | Calithera CALA Initiates Phase I/II Study of Telaglenastat

2019-03-26 07:05:00 | Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib

2019-03-07 20:40:17 | Edited Transcript of CALA earnings conference call or presentation 7-Mar-19 9:30pm GMT

2019-03-07 16:06:00 | Calithera Biosciences Reports Fourth Quarter 2018 Financial Results and Recent Highlights

2019-03-05 07:05:00 | Calithera to Present at Cowen & Company 39th Annual Healthcare Conference

2019-03-04 07:05:00 | Calithera Biosciences to Report Fourth Quarter 2018 Financial Results on Thursday, March 7, 2019

2019-02-27 16:35:00 | Calithera Biosciences Announces CB-708 Preclinical Data Presentation at the AACR Annual Meeting 2019

2019-02-22 08:00:00 | Calithera to Participate in the 8th Annual SVB Leerink Global Healthcare Conference

2019-02-21 16:05:00 | Calithera Biosciences Initiates Phase 1 Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis

2019-02-16 06:00:00 | Updated Results from Phase 1 Study of Telaglenastat CB-839 to be Presented at 2019 ASCO Genitourinary Cancer Symposium

2019-02-04 07:05:00 | Calithera Biosciences Completes Patient Enrollment in Randomized Phase 2 ENTRATA Trial of Telaglenastat CB-839 and Everolimus in Renal Cell Carcinoma

2019-01-28 07:30:00 | Analysis: Positioning to Benefit within Rollins, Hospitality Properties Trust, Exact Sciences, Tenet Healthcare, Entergy, and Calithera Biosciences — Research Highlights Growth, Revenue, and Consolidated Results

2019-01-18 14:19:35 | What Did Calithera Biosciences, Inc.’s NASDAQ:CALA CEO Take Home Last Year?